Rekvina Laboratories Ltd (526075)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Rekvina Laboratories' revenue was ₹0.7 Cr, and net profit ₹-0.1 Cr (a bigger loss than a year earlier); the operating margin was -18.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.7 | — | -7.2% |
| Operating profit | ₹-0.1 | loss widened | loss widened |
| Net profit | ₹-0.1 | loss widened | loss widened |
| EPS (₹) | -0.20 | loss widened | loss widened |
| Operating margin | -18.0% | — | — |
📢 Recent Corporate Announcements
Rekvina Laboratories has appointed Mr. Subrata Samanta as its Chief Financial Officer (CFO) and Key Managerial Personnel, effective October 7, 2026. Mr. Samanta brings over 20 years of experience in finance, costing, and budgeting, having worked at companies including GNFC, Lupin, and Glenmark. This leadership appointment comes at a crucial time as Rekvina operates at micro-scale, generating Rs 2 Cr in TTM revenue with negative net worth (-Rs 1 Cr) and operating losses.
- Appointment of Mr. Subrata Samanta as CFO and KMP effective 07-10-2026
- Candidate brings 20+ years of experience across finance, costing, and ERP implementations
- Board meeting commenced at 06:50 p.m. and concluded at 7:15 p.m. on October 7, 2026
Rekvina Laboratories has announced the resignation of its Managing Director, Mr. Amit Shah, effective September 11, 2026, citing personal reasons and commitments. Additionally, the Board approved shifting the company's registered office within Vadodara effective September 23, 2026. The micro-cap pharmaceutical company operates with a TTM revenue of Rs 2 Cr and negative net worth of Rs -1 Cr.
- Resignation of Managing Director Mr. Amit Shah noted, effective from 11.09.2026
- Reason cited for MD resignation is personal reasons and personal commitment
- Shift of registered office within Vadodara approved with effect from 23.09.2026
- Board meeting commenced at 06:30 pm and concluded at 07:30 pm on 23-09-2026
Rekvina Laboratories has announced the resignation of its Managing Director, Mr. Amit Shah, effective September 11, 2026, citing personal reasons and commitments. Additionally, the Board approved shifting the company's registered office within Vadodara effective September 23, 2026. The micro-cap pharmaceutical company operates with a TTM revenue of Rs 2 Cr and negative net worth of Rs -1 Cr.
- Resignation of Managing Director Mr. Amit Shah noted, effective from 11.09.2026
- Reason cited for MD resignation is personal reasons and personal commitment
- Shift of registered office within Vadodara approved with effect from 23.09.2026
- Board meeting commenced at 06:30 pm and concluded at 07:30 pm on 23-09-2026
Rekvina Laboratories Ltd responded to a BSE surveillance query dated August 14, 2026, regarding significant movement in its share price. The company clarified that it has no undisclosed price-sensitive information, developments, or impending announcements that would impact its stock price. Management stated that all material events have been disclosed per SEBI (LODR) Regulations and the price and volume movement is purely market-driven. Financially, the micro-cap pharma company generated TTM revenue of Rs 2 Cr with negative net worth of Rs -1 Cr.
- Clarification submitted on August 14, 2026, in response to BSE query L/SURV/ONL/PV/SJ/2026-2027/4138
- Company confirmed zero undisclosed price-sensitive information or pending material announcements
- Stated that recent share price and trading volume changes are purely market-driven
- Promoter holding stands at 41.3% with a market capitalization of Rs 32 Cr
Rekvina Laboratories reported a net loss of Rs 12.05 Lacs for the quarter ended June 30, 2026, widening from a loss of Rs 3.54 Lacs in the year-ago period. While revenue from operations grew to Rs 66.85 Lacs from zero in Q1 FY26, it declined sequentially from Rs 72.36 Lacs in Q4 FY26. Total expenses of Rs 78.90 Lacs outpaced income, primarily due to stock-in-trade purchases of Rs 69.76 Lacs. The company also appointed Executive Director Surbhit Shah as the new Chairman of the Board.
- Net loss widened to Rs 12.05 Lacs in Q1 FY27 compared to a loss of Rs 3.54 Lacs in Q1 FY26
- Revenue from operations stood at Rs 66.85 Lacs, up from Nil in the corresponding quarter last year
- Total expenses rose to Rs 78.90 Lacs, with stock-in-trade purchases accounting for 88% of total costs
- Earnings Per Share (EPS) remained negative at -Rs 0.20 for the quarter
- Executive Director Surbhit Shah appointed as Chairman effective August 13, 2026
Rekvina Laboratories reported a net loss of ₹12.05 Lacs for the quarter ended June 30, 2026, compared to a loss of ₹6.05 Lacs in the previous quarter. Revenue from operations stood at ₹66.85 Lacs, a sequential decline of 7.6% from ₹72.36 Lacs in Q4 FY26. The company continues to struggle with profitability, reporting a negative ROCE of -333.3% and a negative net worth of ₹1 Cr. Additionally, the board appointed Executive Director Mr. Surbhit Shah as the Chairman.
- Revenue from operations reached ₹66.85 Lacs in Q1 FY27, compared to zero revenue in the same quarter last year.
- Net loss widened to ₹12.05 Lacs from ₹6.05 Lacs in the preceding quarter (QoQ).
- Total expenses for the quarter were ₹78.90 Lacs, which exceeded the total income of ₹66.85 Lacs.
- Purchases of stock-in-trade accounted for ₹69.76 Lacs, representing 88% of total expenses.
- Appointment of Mr. Surbhit Shah as Chairman of the Board of Directors.
Rekvina Laboratories has approved the allotment of 50.88 lakh equity shares at ₹10 per share to acquire 100% of Radiant Parenterals Limited and raise cash. The acquisition is valued at ₹4.63 crore via a share swap, while ₹0.46 crore was raised through a cash allotment. This is a transformative deal as Radiant Parenterals reported FY25 revenue of ₹31.67 crore, which is approximately 31.7 times Rekvina's TTM revenue of ₹1 crore. Post-acquisition, Radiant becomes a wholly-owned subsidiary, bringing WHO-GMP certified manufacturing capabilities for injectables and syrups into the company.
- Acquisition of 100% stake (18,51,100 shares) in Radiant Parenterals Limited for a total consideration of ₹4.63 crore.
- Radiant Parenterals FY25 revenue stood at ₹31.67 crore, showing massive growth from ₹0.77 crore in FY23.
- Allotment of 46,27,750 shares via share swap and 4,60,000 shares for cash, all at ₹10 per share (including ₹5 premium).
- Target company operates a WHO-GMP & ISO 9001-2015 certified unit in Vadodara specializing in anti-hypertensive and anti-diabetic products.
- Significant increase in promoter-linked shareholding, with two key investors moving from a combined 28.95% to 49.33% stake.
Rekvina Laboratories has scheduled a board meeting on August 13, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is currently in a precarious financial position with a negative net worth of Rs 1 Cr and TTM revenue of only Rs 1 Cr. In the previous quarter (March 2026), it reported revenue of Rs 0.72 Cr and a net loss of Rs 0.06 Cr. Investors should watch for any signs of revenue growth or margin improvement to offset the negative ROCE of -333.3%.
- Board meeting scheduled for August 13, 2026, to consider Q1 results
- Trading window for designated persons closed from July 01, 2026
- Company reported a total revenue of Rs 1.27 Cr for the full year FY26
- Net worth remains negative at Rs -1 Cr as per latest available data
- March 2026 quarter revenue stood at Rs 0.72 Cr with a net loss of Rs 0.06 Cr
The open offer for Rekvina Laboratories by Surbhit Mukesh Shah and others concluded with 14,41,863 shares accepted at ₹10 each, totaling ₹1.44 Cr. This acquisition, combined with a share swap agreement (SEPA), will result in the promoter group holding 77.33% of the expanded share capital. The offer price of ₹10 is at a significant discount to the current market price of ₹25.2. The company remains financially stressed with a negative net worth of ₹1 Cr and TTM revenue of only ₹1 Cr.
- 14,41,863 shares accepted in the open offer at a price of ₹10 per share
- Total consideration paid for the open offer shares amounted to ₹1.44 Cr
- Promoter group holding to reach 77.33% of expanded share capital post-transaction
- Public shareholding reduced significantly from 58.70% to 23.00%
- Underlying transaction involves a share swap of 46,27,750 equity shares at ₹10 each
The open offer for Rekvina Laboratories has concluded with the acquirer group (Surbhit Shah, Amit Shah, and Dhruvalkumar Patel) acquiring 14,41,863 shares at ₹10 per share. This represents approximately 12.97% of the expanded share capital, significantly lower than the 26% originally sought, likely due to the offer price being at a steep discount to the market price. Post-transaction, the total promoter and acquirer group holding has reached 77.33%, while public shareholding has dropped to 23.00%. The acquisition follows a share swap agreement involving Radiant shares valued at ₹25.
- Acquirers accepted 14,41,863 equity shares out of the 28,90,100 shares proposed in the open offer.
- Post-offer promoter and acquirer group holding stands at 77.33%, exceeding the 75% threshold usually permitted.
- The open offer price was ₹10 per share, which is a 60.5% discount to the current market price of ₹25.3.
- Public shareholding has been reduced from 58.70% to 23.00% following the offer and underlying transactions.
- The total actual offer size was ₹1.44 Cr compared to the proposed ₹2.89 Cr.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
